Health Products

Sivem Pharmaceuticals ULC Ranitidine Product Recall (2019-10-17)

· Published by Health Canada · Official notice

Details

Alert type: Drug Recall
Category: Drugs
Issue: Product Safety
Audience: General Public, Healthcare Professionals, Hospitals
Department: Health Canada
Hazard classification: Type I

Summary

Product

A.  Ranitidine 300 mg Tablet;

Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Products

Lot or serial numberBrand nameCompaniesDIN, NPN, DIN-HIMDosage formStrength
K46484, K50204, K46485, K50206, K50590, K50677, K50908, K48440, K48679, K50207, K50594, K50925, K50928, K50932, K50935, K51080B.  Ranitidine 150 mg Tablet
Recalling Firm
Sivem Pharmaceuticals ULC
4705 Dobrin Street
Saint-Laurent
H4R 2P7
Quebec
CANADA
Marketing Authorization Holder
Sivem Pharmaceuticals ULC
4705 Dobrin Street
Saint-Laurent
H4R 2P7
Quebec
CANADA
DIN 02385953TabletRanitidine 150 mg
K50941, K50624, K50947, K50950A.  Ranitidine 300 mg Tablet
Recalling Firm
Sivem Pharmaceuticals ULC
4705 Dobrin Street
Saint-Laurent
H4R 2P7
Quebec
CANADA
Marketing Authorization Holder
Sivem Pharmaceuticals ULC
4705 Dobrin Street
Saint-Laurent
H4R 2P7
Quebec
CANADA
DIN 02385961TabletRanitidine 300 mg

Introduction

A.  Ranitidine 300 mg Tablet;  

B.  Ranitidine 150 mg Tablet

Reason

Affected lots may be manufactured with an API containing an impurity, N-nitrosodimethylamine (NDMA).

Depth of distribution

Wholesalers, Healthcare Establishments, Retailers

For more information

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime